NIDEK Retina Scan Duo 2

The NIDEK Retina Scan Duo 2 combines high-resolution optical coherence tomography (OCT) imaging with integrated fundus photography. Fast scan acquisition, deep-learning B-scan denoising, and Retina Map technology provide clear visualisation of retinal structures, helping clinicians assess diabetic macular oedema, retinal thickening, haemorrhages, and other diabetic retinal changes with confidence.

The Duo 2 supports efficient workflow through integrated macula and optic nerve assessment capabilities within a single platform. Optional OCT angiography and fundus autofluorescence functionality further enhance retinal evaluation, including vascular assessment, without the need for dye injection.

Contact: Designs for Vision (AUS) 1800 225 307

Oertli Surgical Platform

Oertli’s surgical platforms are designed to support ophthalmic surgeons, particularly vitreoretinal specialists, by enhancing their surgical experience.

The OS 4 system offers a versatile solution for posterior segment surgery, featuring a multi-pump fluidics system with proprietary SPEEP (Speed and Precision) function and optional integrated laser and illumination options. Its design supports efficient workflow and precise control during delicate procedures.

To expand on these possibilities, the Faros system balances portability with advanced dual-pump functionality at a low cost. The CataRhex 3 provides a compact alternative for cataracts, for mobile or space-limited environments.

Contact: Device Technologies Account Manager or email eyes@device.com.au.

CSO MS-39

The COBRA+ fundus camera system by CSO, distributed by Eyetek across Australia and New Zealand, delivers crisp, high-resolution retinal imaging with exceptional ease of use, enabling early detection and ongoing management of diabetic eye disease.

Its non-mydriatic functionality enhances patient comfort while streamlining workflow, making it ideal for busy practices.

With reliable performance and advanced imaging precision, practitioners can confidently identify subtle pathological changes and monitor progression over time.

Contact: Eyetek (AUS) 1300 618 336 or email excellent@eyetek.com.au

MonacoPro

MonacoPro by Optos is the only ultra-widefield (UWF) retinal imaging device with integrated Spectral Domain optical coherence tomography (OCT). It produces a 200° single shot optomap image in less than half a second and also provides cross-sectional 40° OCT views of retinal structures. Engineered for efficiency, MonacoPro captures up to five imaging modalities for both eyes in just 90 seconds, optimising workflow, streamlining diagnostics, and delivering superior patient care.

MonacoPro can promptly scan through the central pole and take an UWF image of both eyes. Patients with diabetic retinopathy can be evaluated for both central and peripheral changes on UWF optomap colour RG (red green), as peripheral lesions are indicative of high risk for disease progression.

Visit optos.com or email auinfo@optos.com

iCare Screening Solution

iCare Screening Solution redefines retinal screening through automation and precision. The iCare DRSplus fundus imaging system uses advanced confocal technology to deliver high-resolution, TrueColor fundus images, even through small pupils or media opacities. When paired with iCare Retcad artificial intelligence-powered image analysis, the system provides instantaneous, automated detection of diabetic retinopathy, age-related macular degeneration, and glaucoma.

iCare Illume software bridges these technologies into a streamlined, digital screening workflow.

The core benefit lies in its superior grading capability: the system produces sharp, high-fidelity images that facilitate high-confidence clinical assessment and AI-driven analysis.

Contact: iCare on (AUS) 0435 788 702 or email: inquiry@icare-world.com

Integre Pro Scan

Lumibird Medical’s Integre Pro Scan combines multi-colour photocoagulation with a precise computer-controlled pattern scanning laser in an ergonomically advanced all-in-one laser/slit lamp design. Whether positioning focal treatment in the macular area, or performing panretinal photocoagulation in the periphery, Integre Pro Scan provides a comprehensive pattern and wavelength choice to cover all retinal pathologies.

Contact: Ellex (AUS) 08 7074 8200 or visit lumibirdmedical.com/ophthalmology

Lucentis

Lucentis (ranibizumab) is an established anti-VEGF therapy for the treatment of diabetic eye disease, including diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR). By inhibiting vascular endothelial growth factor (VEGF), Lucentis targets the underlying drivers of pathological neovascularisation and vascular leakage. Administered via intravitreal injection, it delivers localised treatment directly to the retina.

Since October last year, Lucentis has been Pharmaceutical Benefits Scheme (PBS)-reimbursed in Australia for PDR, providing an evidence based alternative to panretinal photocoagulation.

Contact: Novartis (AUS) 1800 635 202 or visit: novartis.com/au-en

For more information, turn to page 48 of this issue or view the Lucentis Product information at: rss.medsinfo.com.au/nv/pi.cfm?product=nvplucin and information on PBS reimbursement is available at: pbs.gov.au/pbs/search?analyse=false&term=ranibizumab&search-type=medicines.

Intalight Dream OCT

The Intalight Dream optical coherence tomography (OCT) device delivers high-resolution, high-speed retinal imaging designed to support the early detection and monitoring of diabetic eye disease. Its deep tissue visualisation enables detailed assessment of retinal and choroidal structures, assisting clinicians in identifying microvascular changes at an earlier stage. Combined with advanced scanning speed and image clarity, it enhances diagnostic confidence and clinical efficiency in busy ophthalmic settings.

Complementing this is the Microclear Sky whole eye imaging platform, which integrates anterior and posterior segment imaging into a unified workflow. This enables comprehensive ocular assessment, supporting longitudinal tracking of diabetic patients and facilitating more informed management decisions.

Visit: ophthalmopro.com.au or contact (AUS) 1300 578 288 or (NZ) 0800 578 288

Revo

The latest SOCT 21.5.0 software update for the Revo optical coherence tomography (OCT) device is a major advancement for diabetic eye care with its new widefield fundus imaging capability. By stitching up to nine internal fixation positions into a seamless mosaic, clinicians gain a significantly broader view of the retina, enabling clearer assessment of peripheral pathology often missed in standard imaging. This expanded field enhances the detection of early diabetic changes, supports more accurate grading, and improves long-term monitoring.

Complemented by upgraded EyeTracking for more stable acquisition and new fundus review filters, the update delivers sharper, more reliable images across diverse examination conditions. Together, these enhancements elevate the Revo FC into a more powerful, comprehensive tool for managing diabetic eye disease.

Visit: Optopol.au or contact sales@optopol.au

Stellaris Elite

Bausch + Lomb has updated its Stellaris Elite Vision Enhancement System to include the new BiBlade+ vitrectomy cutter.

The existing adaptive fluidics and unique ultrasound energy management of the Stellaris Elite system provide efficient lens removal and exceptional chamber stability. In addition, the new BiBlade+ offers vitreoretinal surgeons more streamlined procedures through a 67% increase in cut rates, while optimising control with a reduction in vibration, traction, and the ‘sphere of influence’; all important when working close to the retina.

Contact: Bausch + Lomb (AUS) 1800 251 150 or Customer.Service@bausch.com

Chemist Link

Chemist Link is committed to supporting ophthalmologists and their clinics with reliable and efficient services tailored to the unique demands of ocular drug delivery.

It simplifies intravitreal injections (IVI) by handling e-scripts, supply management, and compliance. Its extensive experience in providing ophthalmic preparations ensures that both practitioners and their patients have access to vital pharmacological treatments when they need them most.

Contact: Chemist Link on (AUS) 0477 001 677 or alaa@chemistlink.com.au

Vabysmo

Vabysmo (faricimab) is the only bispecific antibody registered with the Australian Register of Therapeutic Goods and listed on the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and macular oedema secondary to retinal vein occlusion (RVO).1-3

This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After at least three-weekly initial loading doses for RVO or four initial loading doses for nAMD and DMO, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes.1,4,5

For full information turn to page 5 of this issue.

Contact: Roche Account Manager

Please review the Product Information before prescribing, available at: roche-australia.com/solutions/pharma-solutions/vabysmo. Vabysmo ▼vials and prefilled syringe are listed on the PBS for nAMD, DMO, and RVO. Refer to PBS Schedule for full authority information.

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at tga.gov.au/reporting-problems. Prepared May 2026. M-AU-00005206.

References
1. Vabysmo Approved Product Information. Available at roche-australia.com/productinfo/vabysmo.
2. Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods. Available at: tga.gov.au/resources/artg [accessed February 2025].
3. Department of Health. Pharmaceutical Benefits Scheme. Available at pbs.gov.au.
4. Heier J, et al. Lancet. 2022;399:729-740. doi: 10.1016/S0140-6736(22)00010-1.
5. Wykoff C, et al. Lancet. 2022;399:741-755. doi: 10.1016/S0140-6736(22)00018-6.